Congress Materials – Psych Congress NP Institute 2026
2026 Psych Congress NP Institute | Mar 19-22 | Nashville, TN
This section includes selected Johnson & Johnson Innovative Medicine abstracts, posters, or oral presentations, which have been accepted for congress presentations in the last 2 years or less (as determined by any congress restrictions on length of time materials can be posted). Information about pipeline products or investigational uses of products does not imply FDA approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. Johnson & Johnson does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling. The content contained in this section is subject to congress copyright permissions.
First Onset and Duration of Treatment-Emergent Adverse Events in Patients With Major Depressive Disorder Treated With Adjunctive Lumateperone 42 mg: A Pooled Analysis of 2 Randomized Placebo-Controlled Trials
This document will be available on March 19 2026
Lumateperone as Adjunctive Therapy in Patients With Major Depressive Disorder and Anxious Distress
This document will be available on March 19 2026
Lumateperone for the Prevention of Relapse in Patients with Schizophrenia: Results From a Double-Blind, Placebo-Controlled, Randomized Withdrawal, Phase 3 Trial
This document will be available on March 19 2026
Remission With Lumateperone 42 mg Adjunctive to Antidepressant Therapy in Patients With Major Depressive Disorder: Analysis of Short-Term and Long-Term Trials
This document will be available on March 19 2026
Copies of these presentations are for personal use only and may not be reproduced without written permission from the presentation author.